Earnings season is separating the winners from the wounded. AstraZeneca beat across the board, passed $15 billion in quarterly sales, and reaffirmed its $80 billion 2030 revenue target—one of the few large pharma companies projecting accelerating growth through the end of the decade. GSK found a bright spot in Shingrix while the rest of its vaccine portfolio felt the weight of rising vaccine skepticism. Novartis missed on Tuesday as Entresto fell 42%. Today, all eyes are on Lilly. The consensus expects $15.23 billion in revenue (up 36.8%) and $5.88 EPS, with analyst estimates revised upward over the past 30 days. Foundayo launch data will be the headline number. Beyond earnings, the M&A wave continues. Chiesi’s $1.9 billion acquisition of KalVista adds another rare disease deal to a year that has already produced extraordinary deal volume. And AbbVie entered the KRAS oncology race with an option deal on Kestrel Therapeutics for up to $1.45 billion, establishing competition with Revolution Medicines in what could be one of the largest oncology markets of the decade.
Top Story: Chiesi Acquires KalVista for $1.9B to Expand Rare Disease Portfolio
What Happened: Italy’s Chiesi Group announced a definitive agreement on April 29 to acquire KalVista Therapeutics for $27 per share in cash, a total equity value of approximately $1.9 billion and a 40% premium to KalVista’s Tuesday closing price.
The Asset: An Approved Oral Treatment for Hereditary Angioedema
KalVista’s lead product, Ekterly, is an FDA-approved oral treatment for acute swelling attacks in patients with hereditary angioedema (HAE). HAE is a rare genetic disorder affecting approximately 6,000 to 10,000 people in the United States that causes severe, unpredictable episodes of swelling in the face, extremities, airways, and gastrointestinal tract. Airway attacks can be life-threatening if untreated.
The HAE market has evolved significantly over the past decade. Takeda’s Takhzyro (lanadelumab, injectable prophylaxis) and BioCryst’s Orladeyo (berotralstat, oral prophylaxis) are established players focused on preventing attacks. Ekterly is differentiated as an oral acute treatment—a pill that patients take when an attack begins, rather than a prophylactic therapy taken on a regular schedule to prevent attacks from occurring.
That positioning is commercially important. Patients on prophylactic therapy still experience breakthrough attacks that require acute treatment. An oral option for those breakthroughs—versus the injectable or IV treatments that have historically been the only acute options—addresses a genuine convenience gap. For patients who experience infrequent attacks and prefer on-demand treatment over daily prophylaxis, Ekterly offers a different treatment paradigm entirely.
Why Chiesi Is Paying a 40% Premium
The 40% premium reflects the competitive market for rare disease assets with approved products and defined revenue streams. This follows the same playbook that has defined 2026 M&A across the sector: acquirers paying premium prices for commercial-stage or late-stage rare disease assets with predictable revenue and limited competition.
Chiesi, a privately held Italian pharmaceutical group, has been building its rare disease portfolio as a growth strategy. The KalVista acquisition gives Chiesi an immediate commercial-stage asset in the U.S. market. For KalVista shareholders, the $27 per share offer represents a significant premium but must be weighed against the company’s standalone commercial trajectory in a rare disease market where competing products have substantial head starts.
Our Pro brief analyzes where Ekterly fits in the HAE competitive landscape, how the oral acute treatment positioning differentiates from Takhzyro and Orladeyo, and what the $1.9B valuation implies about the commercial opportunity. [Details below.]
What to Watch
Organon shareholder approval and regulatory clearances will determine the closing timeline. The integration plan—how Chiesi manages a U.S. commercial asset from its Italian headquarters—will determine execution quality. Watch for Ekterly quarterly revenue trajectory and market share gains in the HAE acute treatment segment.
AbbVie Enters the KRAS Race with Kestrel Option Deal
What Happened: AbbVie signed an option-to-acquire agreement with Kestrel Therapeutics for up to $1.45 billion. Kestrel is dosing patients in a Phase 1 trial of KST-6051, an oral pan-KRAS inhibitor for solid tumors. The option structure gives AbbVie the right to acquire Kestrel at a later date, likely contingent on clinical data.
Why This Matters for the KRAS Landscape
AbbVie’s entry into KRAS oncology establishes a second major pharma company competing directly with Revolution Medicines in the RAS-targeted oncology space. KST-6051 represents a distinct chemical approach to pan-KRAS inhibition. Unlike Revolution’s daraxonrasib (which targets the active RAS conformation across multiple variants) or zoldonrasib (G12D-selective), KST-6051 takes a different path to the same therapeutic goal: blocking the KRAS signaling that drives more than 90% of pancreatic cancers and significant portions of lung and colorectal cancers.
The option structure is strategically smart for AbbVie. By securing the right to acquire rather than committing to a full acquisition now, AbbVie limits its downside if Phase 1 data are disappointing while maintaining upside if the data demonstrate differentiated activity. The $1.45 billion total potential value is modest relative to what a validated KRAS program could ultimately be worth given the size of the market opportunity. If KST-6051 produces positive data that validates the pan-KRAS approach, AbbVie’s option price could look like a significant bargain in hindsight. If the data disappoint, AbbVie walks away with limited capital at risk. This is AbbVie’s first entry into the KRAS oncology space, and the option structure reflects the prudent approach of a company exploring a new therapeutic area rather than making an all-in commitment.
The Competitive Landscape Is Forming
Revolution Medicines sued Erasca for patent infringement earlier this week, signaling how aggressively it is defending its position. Erasca is developing its own RAS inhibitor for pancreatic cancer. With AbbVie now entering through the Kestrel option deal, the KRAS space has at least three distinct competitive programs in clinical development. The market opportunity is enormous—RAS mutations are the most common oncogenic driver across multiple solid tumor types—and the competitive dynamics are intensifying four weeks before Revolution presents full Phase 3 data at the ASCO plenary.
Our Pro brief maps the KRAS competition between Revolution Medicines, AbbVie/Kestrel, and Erasca, including mechanism differentiation, clinical timelines, and market sizing. [Details below.]
Earnings: AstraZeneca Beats Q1, Bullish on $80B 2030 Target
What Happened: AstraZeneca reported Q1 sales above $15 billion, beating analyst expectations. Key Phase 3 data wins during the quarter reinforced confidence in the pipeline. Management expressed increasing conviction that the company’s $80 billion revenue target by 2030 is achievable.
What Is Driving AstraZeneca’s Confidence
AstraZeneca’s growth is being driven by its oncology franchise—anchored by Enhertu, Tagrisso, and Imfinzi—alongside rare disease launches and respiratory/immunology expansion. The company is one of the few large pharma companies projecting accelerating growth through the end of the decade, a contrast to the patent cliff challenges facing other major players.
The $80 billion target by 2030 implies roughly a doubling of current revenue over the next four years. That requires sustained double-digit growth across multiple franchises and successful execution of late-stage pipeline programs. The Q1 beat and pipeline progress give management credibility on the target, but the path requires continued flawless execution across oncology, rare disease, and respiratory—any single franchise stumble could derail the trajectory.
Earnings: GSK Beats on Shingrix, Vaccine Skepticism Weighs on the Rest
What Happened: GSK reported a Q1 sales beat driven by Shingrix (shingles vaccine) jumping 20% to nearly $1.4 billion. However, sales for most of GSK’s other vaccines slumped as vaccine skepticism continues to climb in the U.S., a dynamic that has intensified under the current administration’s public health messaging.
CEO Luke Miels told Fierce Biotech that oncology may offer “the most tempting targets” under GSK’s new strategy of trying to outperform established blockbusters rather than build from scratch. The comment signals a strategic pivot at GSK: moving from vaccine-dependent growth toward oncology M&A and pipeline development as the primary growth engine.
Why This Matters: The divergence within GSK’s vaccine portfolio—Shingrix thriving while other vaccines decline—illustrates a broader challenge for vaccine-dependent pharma companies. Shingrix is insulated because shingles is a condition that predominantly affects older adults who are less susceptible to vaccine hesitancy. Childhood and adult preventive vaccines face headwinds that are unlikely to reverse in the near term. GSK’s strategic shift toward oncology is a direct response to this dynamic.
Clinical Updates
Boehringer Ingelheim and Zealand Pharma Hit Obesity Phase 3
Boehringer Ingelheim and Zealand Pharma’s dual-acting obesity shot met its primary endpoint in a Phase 3 trial. BioPharma Dive described the drug as “more akin” to Novo Nordisk’s Wegovy in terms of weight-loss magnitude, positioning it as a potential competitor in the injectable GLP-1 space. Full results are expected at a medical congress later this year. The obesity market continues to attract new entrants alongside Foundayo, Wegovy, and Kailera’s ribupatide.
Lilly Reports This Morning
Eli Lilly reports Q1 2026 earnings before the bell today. Consensus expectations: $5.88 EPS and $15.23 billion in revenue (36.8% year-over-year growth). Analyst estimates have been revised upward over the past 30 days.
The five numbers that will define the call:
Foundayo TRx trajectory: We have Week 1 data (1,390 prescriptions, roughly two days of capture). Lilly will provide data through mid-April. The acceleration curve from Week 1 to Week 3-plus is the critical metric—a steep ramp validates the launch thesis, a flat curve raises concerns about Novo’s entrenched position with oral Wegovy.
Zepbound/Mounjaro combined revenue: Still the growth engine powering the entire company. Supply chain commentary and demand trends will inform whether the injectable franchise can sustain growth alongside the oral Foundayo launch.
ACHIEVE-4 filing status: Is the type 2 diabetes CNPV submission on track for end of Q2? Any delay would push the diabetes label expansion into H2 and defer the addressable market expansion from 40 million obesity patients to an additional 37 million with T2D.
M&A commentary: Six deals in three months. How is Lilly managing parallel integrations across Orna, Centessa, Kelonia, CrossBridge, Ajax, and the Profluent collaboration? Is a seventh deal on the horizon, or is the company shifting to integration mode?
Full-year guidance: Any revision to 2026 guidance incorporating Foundayo launch, ACHIEVE-4, and deal costs will reset consensus estimates and potentially move the stock more than the actual Q1 numbers.
We will cover the full results in detail in tomorrow’s email.
Strategic Themes
1. KRAS Oncology Is Becoming a Multi-Company Race
AbbVie’s option deal with Kestrel, Revolution’s patent lawsuit against Erasca, and Revolution’s own expanding platform (daraxonrasib, zoldonrasib, RM-055) collectively establish KRAS as a competitive oncology market with multiple participants rather than a single-company franchise. RAS mutations drive more than 90% of pancreatic cancers and significant portions of lung and colorectal cancers. The market opportunity is large enough to support multiple winners, but the competitive dynamics will be defined by which mechanisms demonstrate the best efficacy, safety, and convenience profiles. Revolution has a substantial clinical data lead, but early-stage competitors with differentiated approaches could carve out meaningful positions if their data support it.
2. Earnings Season Is Revealing Who Prepared for the Patent Cliff and Who Did Not
AstraZeneca sees $80 billion by 2030 because it invested in pipeline diversification years ago. Novartis is absorbing a $4 billion erosion because Entresto’s patent expired. GSK is pivoting to oncology because vaccine skepticism is undermining its traditional growth engine. The divergence across these three companies illustrates that the patent cliff is not a universal threat—it is a specific challenge for companies that failed to diversify early enough. The companies reporting the strongest quarters are those that built pipeline depth before their blockbusters went generic.
3. Rare Disease M&A Continues to Command Premium Prices
Chiesi’s 40% premium for KalVista’s Ekterly follows the pattern established across 2026: approved rare disease products with defined revenue streams and limited competition attract premium valuations. The math is straightforward. Rare disease products have long IP runways, small but loyal patient populations, high per-patient pricing, and minimal competition. These characteristics create predictable, durable revenue streams that acquirers are willing to pay premium prices to own.
4. Everything Converges on Lilly This Morning
Foundayo launch data. ACHIEVE-4 diabetes filing. Six-deal integration. Zepbound/Mounjaro growth. Tariff positioning. Full-year guidance. No single earnings call this quarter carries the density of catalysts, strategic questions, and competitive implications that Lilly’s does. The market’s reaction will set the tone for the entire pharma sector heading into ASCO.
Frequently Asked Questions
What is the Chiesi/KalVista deal?
Chiesi Group is acquiring KalVista Therapeutics for $27 per share ($1.9 billion), a 40% premium. KalVista’s lead product Ekterly is an approved oral treatment for acute attacks in hereditary angioedema. The deal deepens Chiesi’s rare disease portfolio and gives it a commercial-stage U.S. asset.
What is hereditary angioedema?
A rare genetic disorder affecting approximately 6,000 to 10,000 people in the U.S. that causes severe, unpredictable swelling episodes. The HAE market includes Takeda’s Takhzyro (injectable prophylaxis) and BioCryst’s Orladeyo (oral prophylaxis). Ekterly is differentiated as an oral acute treatment for breakthrough attacks.
What is the AbbVie/Kestrel deal?
AbbVie signed an option-to-acquire agreement with Kestrel Therapeutics for up to $1.45 billion. Kestrel’s KST-6051 is an oral pan-KRAS inhibitor in Phase 1 for solid tumors. The option structure limits AbbVie’s downside if data are disappointing while maintaining upside if the drug demonstrates differentiated activity. This is AbbVie’s first entry into KRAS oncology.
How did AstraZeneca perform in Q1?
AstraZeneca beat estimates with sales above $15 billion and reaffirmed its $80 billion 2030 revenue target. Oncology (Enhertu, Tagrisso, Imfinzi), rare disease, and respiratory/immunology are the growth drivers. AstraZeneca is one of the few large pharma companies projecting accelerating growth through the end of the decade.
What happened with GSK’s vaccine business?
Shingrix jumped 20% to nearly $1.4 billion, driving a Q1 sales beat. But most other GSK vaccines declined as U.S. vaccine skepticism has intensified. CEO Luke Miels signaled a strategic pivot, telling Fierce Biotech that oncology may offer “the most tempting targets” for growth.
What is the Boehringer/Zealand obesity Phase 3 result?
Their dual-acting obesity shot met its primary endpoint. BioPharma Dive described the weight-loss magnitude as “more akin” to Wegovy. Full results are expected at a medical congress later this year. The drug would join Foundayo, Wegovy, Ozempic, Zepbound, and Kailera’s ribupatide in an increasingly competitive obesity market.
What are Lilly earnings expectations?
Consensus: $5.88 EPS and $15.23 billion in revenue (36.8% year-over-year growth). The most important numbers will be Foundayo TRx trajectory through mid-April, Zepbound/Mounjaro revenue, ACHIEVE-4 diabetes filing timeline, M&A integration commentary, and full-year guidance. Full coverage in tomorrow’s email.
What is the KRAS competitive landscape now?
Three distinct programs: Revolution Medicines (daraxonrasib, multi-selective RAS(ON), Phase 3 positive plus ASCO plenary May 31), AbbVie/Kestrel (KST-6051, pan-KRAS, Phase 1), and Erasca (RAS inhibitor, sued by Revolution for patent infringement). Revolution has the clinical data lead but competition is intensifying. The KRAS market could exceed billions annually at maturity given that RAS mutations drive more than 90% of pancreatic cancers.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
KRAS Competition Map. We map the three-way competitive dynamic between Revolution Medicines, AbbVie/Kestrel, and Erasca, including mechanism differentiation, clinical development timelines, patent positioning, and market sizing across pancreatic, lung, and colorectal cancers. If you are positioning around the RAS oncology thesis, this is the competitive framework.
Earnings Scorecard: Patent Cliff Management. We compare AstraZeneca’s pipeline-driven acceleration, Novartis’s $4B erosion, and GSK’s vaccine skepticism pivot into a single framework for how large pharma is navigating—or failing to navigate—the patent cliff challenge. The winners invested in diversification five years ago. The losers are scrambling now.
Lilly Preview: The Five Numbers Dropping This Morning. We lay out what Foundayo TRx data, Zepbound/Mounjaro revenue, ACHIEVE-4 filing status, M&A commentary, and guidance revisions need to show to support Lilly’s current valuation and keep the momentum narrative intact.
Plus: Chiesi/KalVista HAE competitive analysis, Boehringer/Zealand obesity landscape implications, Revolution patent enforcement strategy, and the updated catalyst calendar through ASCO and H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
